Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2026)

Contineum Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 6.66% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $66.9 million, a 13.17% increase from a year earlier, with the FY2025 full-year figure at $68.1 million, up 33.73% from the prior year.
• Operating Expenses eased to $16.9 million in Q1 2026 per CTNM's latest filing, from $17.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.1 million in Q1 2025 and bottomed at $5.1 million in Q1 2023.
• The 4-year median for Operating Expenses is $13.0 million (2024), against an average of $13.1 million.
• Across the five-year window, Operating Expenses jumped 94.13% in 2024 and decreased 6.66% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $9.7 million in 2023, then jumped by 76.18% to $17.0 million in 2024, then climbed by 0.4% to $17.1 million in 2025, then fell by 1.23% to $16.9 million in 2026.
• Per Business Quant, the three latest CTNM Operating Expenses figures stand at $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $14.9 million (Q3 2025).